Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

MadisonRamsey Jul. 28 at 8:18 PM

$MCD $RGTI $JNJ $VRT $LRCX direction

0 · Reply

SenefAS Jul. 28 at 8:10 PM

When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ

0 · Reply

harmongreg Jul. 28 at 7:42 PM

Johnson & Johnson Reaches a Settlement https://open.substack.com/pub/gregharmon/p/johnson-and-johnson-reaches-a-settlement?r=2xa2&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true $JNJ

0 · Reply

GoforProMIS Jul. 28 at 6:59 PM

$PMN with today’s presentation at the Webinar ProMIS is the new Sheriff in town for Alzheimer and several other neurological diseases no Aria of 144 Probants and best best results in Plasma pTau217 and CSF MTBR-tau243 just wonder who will takeover this 💎 $PFIZER.NSE $JNJ $BMY https://d1io3yog0oux5.cloudfront.net/_a52bc4a1574a61db158bebe9c6f0d9df/promisneurosciences/db/933/8992/pdf/Confidential+and+Final+-+PRECISE-AD+Interim+Results+Presentation.pdf

0 · Reply

Jack90 Jul. 28 at 6:36 PM

Time to look for boring dividends $NKE $DIS $WHR $PFE $JNJ and so on When all running out of semi, money rotated to safe house

1 · Reply

Orbit100 Jul. 28 at 6:09 PM

$JNJ All companies will issue long list of warnings and side affects and raised prices on all their products to avoid the example of JNJ baby powder lawsuit. JNJ wants to move on and to pay $5.5 billions as over 76000 patients want to get paid including the lawyers. The stock will fly to the moon when the court accepts JNJ's offer.

0 · Reply

Orbit100 Jul. 28 at 6:05 PM

$JNJ I am loading up JNJ stock today. The frivolous lawsuit of its baby powder shows how broken the courts are. I am sure many of you use its baby powders for many generations. I use it since my young age and for my babies and I am a senior now and my babies are all grown up to be middle age and all cancer free.

0 · Reply

Orbit100 Jul. 28 at 5:53 PM

$JNJ People wonder why our cost of health care in America so high. This is why. The juries and the courts awarded people' frivolous suits with ridiculous amount of money. JNJ has been dragged through muds and sued for its baby powder for years. They gave up and offered to settled to pay $5.5 billion dollars to those who claimed that got cancer by using the baby powder. I used JNJ baby powder on my babies and myself and my babies now are 43 to 44 year of age. No cancer.

0 · Reply

KingTrades09 Jul. 28 at 5:52 PM

$JNJ added some puts today on this daily ugly candle.

0 · Reply

Suite510 Jul. 28 at 5:24 PM

$JNJ $KVUE $SPX Reality sinks in lol 😝 Requires 95% of plaintiffs approve 99% of the lawyers approved because they are getting 40-50% of the 5.5 Billion lol 😂 plus the PSC lawyers are getting 5-8% means plaintiffs getting 50% 🤣🙈🤔 good luck Junk n Junk 🤣💰👋

0 · Reply

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 4 hours ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

2026-07-28T06:59:19.000Z - 14 hours ago

J&J Strikes $5.5B Talc Settlement after Years of Lawsuits; JNJ Stock Rises

Jul 28, 2026, 1:03 AM EDT - 16 hours ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 16 hours ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 19 hours ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 22 hours ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 22 hours ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 1 day ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

2026-07-23T12:35:56.000Z - 5 days ago

Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 5 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 6 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

2026-07-22T14:32:43.000Z - 6 days ago

Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon

ISRG MDT

2026-07-22T14:24:28.000Z - 6 days ago

Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

ISRG MDT

Jul 22, 2026, 7:21 AM EDT - 6 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

2026-07-22T11:05:32.000Z - 6 days ago

Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA

Jul 22, 2026, 7:00 AM EDT - 6 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 6 days ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

2026-07-21T17:35:16.000Z - 7 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Steady Cash Flow, 7/21/26

KO NEE

2026-07-16T17:30:35.000Z - 12 days ago

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

2026-07-16T17:25:12.000Z - 12 days ago

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

2026-07-16T14:15:34.000Z - 12 days ago

Johnson & Johnson price target raised to $305 from $265 at Scotiabank

2026-07-16T12:50:35.000Z - 12 days ago

Johnson & Johnson price target raised to $265 from $258 at Raymond James

Jul 16, 2026, 8:11 AM EDT - 12 days ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 12 days ago

DePuy Synthes Acquires Expanding Innovations™

2026-07-16T11:50:11.000Z - 12 days ago

Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs

2026-07-16T11:30:25.000Z - 12 days ago

Johnson & Johnson price target raised to $270 from $260 at JPMorgan

Jul 15, 2026, 12:09 PM EDT - 13 days ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 13 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 13 days ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 13 days ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 13 days ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 13 days ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 13 days ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 13 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 13 days ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 13 days ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 13 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 19 days ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 20 days ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 21 days ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 4 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 4 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 4 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 6 weeks ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 6 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 6 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 6 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Jun 11, 2026, 2:03 AM EDT - 6 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 6 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 7 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 7 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 8:08 AM EDT - 7 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 7 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 3, 2026, 12:04 AM EDT - 7 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 7 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 7 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 2 months ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 2 months ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 2 months ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 2 months ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 2 months ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

MadisonRamsey Jul. 28 at 8:18 PM

$MCD $RGTI $JNJ $VRT $LRCX direction

0 · Reply

SenefAS Jul. 28 at 8:10 PM

When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ

0 · Reply

harmongreg Jul. 28 at 7:42 PM

Johnson & Johnson Reaches a Settlement https://open.substack.com/pub/gregharmon/p/johnson-and-johnson-reaches-a-settlement?r=2xa2&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true $JNJ

0 · Reply

GoforProMIS Jul. 28 at 6:59 PM

0 · Reply

Jack90 Jul. 28 at 6:36 PM

Time to look for boring dividends $NKE $DIS $WHR $PFE $JNJ and so on When all running out of semi, money rotated to safe house

1 · Reply

Orbit100 Jul. 28 at 6:09 PM

0 · Reply

Orbit100 Jul. 28 at 6:05 PM

0 · Reply

Orbit100 Jul. 28 at 5:53 PM

0 · Reply

KingTrades09 Jul. 28 at 5:52 PM

$JNJ added some puts today on this daily ugly candle.

0 · Reply

Suite510 Jul. 28 at 5:24 PM

0 · Reply

profit_guru Jul. 28 at 5:23 PM

$JNJ - looks like it will close red from Those overbought levels…near term 255..imo

0 · Reply

twitsblast Jul. 28 at 4:42 PM

$JNJ $JOBY $KDP 🚨 $CHAI Trading Volume Soars 1,300% Following Expanded TikTok Partnership 🚀

0 · Reply

BarkingPuppy Jul. 28 at 3:54 PM

$ELTP $MRNA $LLY $JNJ $PFE You Stopping by Today? The Big boys are shopping Midsize Pharma Companies. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry. Elite owns multiple generic products, some of which are licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. ITS ALL ABOUT SEQUESTOX AND ELITE'S ART TECHNOLOGY

0 · Reply

Wallstfan Jul. 28 at 3:36 PM

$JNJ looks like selling now and possibly a rotation back to tech. We will trade sideways here and hit $300 by Nov

0 · Reply

LiveTradePro Jul. 28 at 3:20 PM

$JNJ New ATH https://share.trendspider.com/chart/JNJ/66824syqe8

0 · Reply

Stocktwits52wHighs Jul. 28 at 2:31 PM

$JNJ printed a new 52-week high today

0 · Reply

HuddyTrades Jul. 28 at 2:03 PM

$JNJ Anyone have any long term price targest on this, I'm thinking $330-350?

0 · Reply

yellowstar16 Jul. 28 at 1:48 PM

$JNJ Retirement portfolios largest equity getting some air today. And it’s been a solid year. Long.

0 · Reply

JFDI Jul. 28 at 1:39 PM

$JNJ ATH Boomers be boomin

0 · Reply

Suite510 Jul. 28 at 1:12 PM

$JNJ $KVUE $SPX Settlement requires 95% approval rate, deal was pushed by the court magistrate and PSC lawyers 😆💰 Never going to be approved by plaintiffs lol 😂 lowball offer

2 · Reply

OpenOutcrier Jul. 28 at 1:11 PM

$JNJ (+2.0% pre) Johnson & Johnson to pay $5.5BN settlement in talc cancer lawsuit https://ooc.bz/l/108846

0 · Reply

Phase3 Jul. 28 at 12:33 PM

$JNJ $80 grand each?

0 · Reply

Market Cap	634.06B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	23.87
Forward PE	22.20
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	9,783,022
Avg Vol	8,485,332
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	88%
Beta	0.24
Analysts	Strong Sell
Price Target	$273.52